Sponsor or institution

Clinical trials and research at Astellas Pharma Inc

• 32Clinical trials
• 26Countries

Newest trials

All recruiting trials (32)

• Can fezolinetant reduce hot flashes for Indian women going through menopause

  This study tests whether fezolinetant can lessen hot flashes and night sweats in Indian menopausal women who have persistent vasomotor symptoms.

  Recruiting Phase 3 Astellas Pharma Inc · Bengaluru, Karnataka · NCT07829653

• How fezolinetant is processed in men with prostate cancer taking hormone therapy

  This study tests how fezolinetant behaves in the body of men with prostate cancer who are on hormone therapy to help manage hot flashes.

  Recruiting Phase 1 Astellas Pharma Inc · Plovdiv, Plovdiv Province · NCT07783282

• ASP2767 safety and potential nerve-protection gene therapy for open-angle glaucoma

  This study tests the safety and tolerability of ASP2767 gene therapy in people with open-angle glaucoma to see if it can help protect optic nerve and vision.

  Recruiting Phase 1/2 Astellas Pharma Inc · Boston, Massachusetts · NCT07770685

• ASP2020 eye injection safety in Stargardt-type macular dystrophy

  A small study will test whether a single ASP2020 eye injection is safe and may help people with Stargardt-type macular dystrophy.

  Recruiting at 4 sites Phase 1 Astellas Pharma Inc · Phoenix, Arizona and 3 other locations · NCT07734064

• ASP388B given alone or with standard therapies in solid tumors

  This early study tests ASP388B, first given alone or with standard cancer treatments, to see if it is safe and to find workable dose levels for solid tumors.

  Recruiting at 4 sites Phase 1/2 Astellas Pharma Inc · Lake Success, New York and 3 other locations · NCT07730021

• A combination therapy with ASP2138 and standard chemotherapy plus pembrolizumab for advanced stomach and GEJ cancer

  This study tests ASP2138 along with pembrolizumab and chemotherapy to see if it helps people with advanced, inoperable, or metastatic gastric or GEJ cancer that is HER2-negative and CLDN18.2-positive.

  Recruiting at 12 sites Phase 3 Astellas Pharma Inc · Saint Louis Park, Minnesota and 11 other locations · NCT07673887

• Fezolinetant use for menopausal hot flashes in Canada

  This observational study in Canada follows women with menopausal vasomotor symptoms who are taking fezolinetant in routine care to see how well it helps after 12 weeks and over a year.

  Recruiting at 2 sites Astellas Pharma Inc · Montreal and 1 other locations · NCT07602530

• Enfortumab vedotin plus pembrolizumab versus chemoradiotherapy for muscle-invasive bladder cancer

  This trial tests whether combining enfortumab vedotin with pembrolizumab can help people with non-metastatic muscle-invasive bladder cancer keep their bladder and control the cancer better than standard concurrent chemoradiotherapy.

  Recruiting at 29 sites Phase 3 Astellas Pharma Inc · Little Rock, Arkansas and 28 other locations · NCT07566156

• KRAS G12D NSCLC: setidegrasib plus docetaxel against docetaxel alone

  This study tests whether adding setidegrasib to docetaxel helps people with KRAS G12D–mutant non-small cell lung cancer who have already progressed after platinum-based therapy.

  Recruiting at 30 sites Phase 3 Astellas Pharma Inc · Glendale, California and 29 other locations · NCT07566052

• ASP546C for adults with gastric/GEJ, pancreatic, and select other solid tumors

  This trial will test the experimental drug ASP546C given every three weeks to find the best dose and check safety in adults with gastric/GEJ cancer, pancreatic cancer, or certain other solid tumors.

  Recruiting at 21 sites Phase 1/2 Astellas Pharma Inc · Birmingham, Alabama and 20 other locations · NCT07488676

• Enfortumab vedotin plus pembrolizumab to help people with muscle-invasive bladder cancer keep their bladder

  This trial tests whether giving enfortumab vedotin together with pembrolizumab can let people with muscle-invasive bladder cancer avoid bladder removal.

  Recruiting at 68 sites Phase 2 Astellas Pharma Inc · Little Rock, Arkansas and 67 other locations · NCT07475806

• Tracking how Stargardt-type macular dystrophy progresses in children and adults

  This project will follow children and adults with Stargardt-type macular dystrophies over time to see how their vision and eye findings change.

  Recruiting at 15 sites Astellas Pharma Inc · Phoenix, Arizona and 14 other locations · NCT07425574

• Setidegrasib with mFOLFIRINOX or NALIRIFOX for KRAS G12D metastatic pancreatic cancer

  This trial tests whether adding setidegrasib to mFOLFIRINOX or NALIRIFOX helps people with metastatic pancreatic cancer who have a KRAS G12D mutation.

  Recruiting at 104 sites Phase 3 Astellas Pharma Inc · Gilbert, Arizona and 103 other locations · NCT07409272

• ASP5541 with prednisone and ADT for Chinese men with prostate cancer

  This study tests whether giving ASP5541 together with prednisone and ongoing androgen-deprivation therapy is safe and how the medicine behaves in Chinese men with metastatic prostate cancer.

  Recruiting Phase 1 Astellas Pharma Inc · Beijing, Beijing Municipality · NCT07339267

• ASP2246 for people with persistent movement problems after stroke

  This study will test whether a new drug called ASP2246, delivered directly into the damaged part of the brain, is safe and tolerated in adults who still have trouble moving 3–12 months after an ischemic stroke.

  Recruiting at 5 sites Phase 1/2 Astellas Pharma Inc · Sendai, Miyagi and 4 other locations · NCT07318714

• ASP2998 alone and with standard cancer medicines for advanced solid tumors

  This early-phase trial will test whether ASP2998, given alone or with pembrolizumab, enfortumab vedotin, or carboplatin, is safe and can shrink or slow advanced solid tumors.

  Recruiting at 9 sites Phase 1/2 Astellas Pharma Inc · Celebration, Florida and 8 other locations · NCT07287995

• Gilteritinib for adults with advanced ALK-positive non-small cell lung cancer

  This phase 1 trial tests whether gilteritinib can help adults with advanced ALK-positive non-small cell lung cancer who have progressed after prior ALK inhibitor treatment.

  Recruiting at 16 sites Phase 1 Astellas Pharma Inc · Fullerton, California and 16 other locations · NCT07140016

• Finding a suitable dose of ASP5834 for adults with solid tumors

  This trial tests different doses of the experimental drug ASP5834, given alone or with panitumumab, in adults whose advanced solid tumors have certain KRAS mutations to find a safe, tolerable dose.

  Recruiting at 22 sites Phase 1 Astellas Pharma Inc · Santa Monica, California and 21 other locations · NCT07094204

• ASP2957 gene therapy for ventilator-dependent boys with X-linked myotubular myopathy

  This trial will try a one-time AAV gene therapy, ASP2957, in infants and young boys with XLMTM who need a ventilator to breathe most of the day.

  Recruiting at 5 sites Phase 1/2 Astellas Pharma Inc · Chicago, Illinois and 4 other locations · NCT07052929

• ASP2138 before surgery, then standard chemotherapy for resectable pancreatic ductal cancer

  This trial will try giving one injection of ASP2138 before surgery and then standard chemotherapy after surgery for adults with CLDN18.2-positive resectable pancreatic ductal adenocarcinoma.

  Recruiting at 3 sites Phase 1 Astellas Pharma Inc · Boston, Massachusetts and 2 other locations · NCT07024615

• Phase 2 test of ASP5541 for men with advanced prostate cancer

  This study will test whether an injectable form of abiraterone (ASP5541) is safe and works as well or better than the standard oral abiraterone for men with metastatic prostate cancer who are on hormone therapy, with or without prednisone.

  Recruiting at 54 sites Phase 2 Astellas Pharma Inc · Huntsville, Alabama and 53 other locations · NCT07005154

• Observing the safety of VYLOY in patients with gastric or GEJ cancer in South Korea

  This study is testing how safe the drug VYLOY is for people in South Korea with advanced stomach or gastroesophageal junction cancer who are receiving it as part of their regular treatment.

  Recruiting at 15 sites Astellas Pharma Inc · Goyang-si, Gyeonggi-do and 14 other locations · NCT06902545

• Zolbetuximab plus pembrolizumab and chemotherapy for stomach and gastroesophageal junction cancer

  This trial will test whether adding zolbetuximab to pembrolizumab and standard chemotherapy helps adults with Claudin 18.2-positive, HER2-negative locally advanced or metastatic stomach or gastroesophageal junction cancer.

  Recruiting at 187 sites Phase 3 Astellas Pharma Inc · Birmingham, Alabama and 252 other locations · NCT06901531

• Enfortumab vedotin for advanced urothelial (bladder) cancer in Indian adults

  This trial will test enfortumab vedotin given by IV infusion in Indian adults whose urothelial cancer has spread and progressed after prior treatments.

  Recruiting at 15 sites Phase 4 Astellas Pharma Inc · Patna, Bihar and 14 other locations · NCT06862219

• Monitoring liver health in boys with a genetic muscle condition

  This study looks at how often boys with a genetic muscle condition called X-Linked Myotubular Myopathy have liver problems to better understand their health over time.

  Recruiting at 11 sites Astellas Pharma Inc · Santa Monica, California and 10 other locations · NCT06581146

• Survey of Adults in South Korea with Urothelial Cancer Receiving PADCEV Injection

  This study looks at how well PADCEV Injection works and its side effects in adults with advanced urothelial cancer in South Korea over 48 weeks.

  Recruiting at 18 sites Astellas Pharma Inc · Goyang-si, Gyeonggi-do and 21 other locations · NCT06011954

• Evaluating AMX-500 for advanced prostate cancer

  This study is testing a new drug called AMX-500 to see if it is safe and effective for people with advanced prostate cancer that has spread and doesn't respond to hormone treatment.

  Recruiting at 25 sites Phase 1 Astellas Pharma Inc · Duarte, California and 25 other locations · NCT05997615

• Testing ASP1002 for treating advanced solid tumors in adults

  This study is testing a new drug called ASP1002 to see if it can safely help adults with advanced solid tumors that have high levels of claudin 4.

  Recruiting at 12 sites Phase 1 Astellas Pharma Inc · New Haven, Connecticut and 14 other locations · NCT05719558

• Testing ASP3082 in Adults with Advanced Solid Tumors

  This study is testing a new drug called ASP3082 to see if it can help adults with advanced solid tumors that have a specific genetic mutation, and it will look at how safe it is and the best way to use it.

  Recruiting at 64 sites Phase 1 Astellas Pharma Inc · Duarte, California and 67 other locations · NCT05382559

• Testing ASP2138 for stomach and pancreatic cancer treatment

  This study is testing a new drug called ASP2138 to see if it can help adults with stomach or pancreatic cancer by boosting their immune response when used alone or with standard treatments.

  Recruiting at 42 sites Phase 1 Astellas Pharma Inc · Orange, California and 45 other locations · NCT05365581

• Testing a new injection for men with advanced prostate cancer

  This study is testing a new injection for men with advanced prostate cancer to see how well it works and how safe it is.

  Recruiting at 15 sites Phase 1 Astellas Pharma Inc · Tucson, Arizona and 24 other locations · NCT04729114

• Testing a new treatment for vision loss in older adults with age-related macular degeneration

  This study is testing a new treatment using stem cells to see if it can help older adults with vision loss from age-related macular degeneration feel better and improve their sight.

  Recruiting at 13 sites Phase 1 Astellas Pharma Inc · Phoenix, Arizona and 19 other locations · NCT03178149

Quick answers

How many clinical trials run by Astellas Pharma Inc are recruiting right now?

32, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 26 countries. The most sites are in United States (24 trials), Japan (13 trials), South Korea (10 trials), China (9 trials), Spain (9 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 12, Phase 3: 6, Phase 1/2: 6, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →